Isoliquiritigenin

Isoliquiritigenin is a chalcone-type flavonoid found primarily in licorice root (Glycyrrhiza species) that exerts anti-inflammatory and metabolic effects largely through inhibition of NF-κB signaling and modulation of AMPK pathways. Its broad bioactivity spans glycemic regulation, lipid metabolism, and inflammatory cytokine suppression, supported by both in vitro mechanistic data and early-stage human trials.

Origin & History

Isoliquiritigenin (ILTG) is a naturally occurring chalcone flavonoid (C15H12O4) primarily sourced from the roots of Glycyrrhiza glabra (licorice) and related Glycyrrhiza species, where it occurs as a minor component alongside liquiritigenin and other chalcones. Extraction typically involves ethanol or methanol solvent extraction of licorice root, followed by chromatographic purification to isolate the yellow crystalline powder.

Historical & Cultural Context

Isoliquiritigenin is a marker compound in Glycyrrhiza glabra root, used in Traditional Chinese Medicine as 'gan cao' for over 2,000 years to harmonize formulas and treat cough, gastric ulcers, and inflammation. In Ayurveda ('yashtimadhu') and Japanese Kampo ('kanzo'), licorice preparations have addressed respiratory and digestive issues for centuries, though isolation of ILTG itself is a 20th-century development.

Health Benefits

• Metabolic support: Reduced serum triglycerides (-15%) and improved insulin sensitivity (HOMA-IR -12%) in postmenopausal women with metabolic syndrome (moderate evidence, PMID: 23380324)
• Anti-inflammatory effects: Mild reduction in C-reactive protein (-20%) observed in healthy volunteers (preliminary evidence, PMID: 28494188)
• Antioxidant activity: Activates Nrf2/HO-1 pathway and reduces reactive oxygen species via Keap1 dissociation (preclinical evidence only)
• Potential anticancer properties: Inhibits PI3K/Akt/mTOR pathway and induces apoptosis via caspase-3 activation (preclinical evidence only)
• Traditional respiratory support: Component of licorice used for cough and respiratory issues in Traditional Chinese Medicine for >2,000 years (traditional use only)

How It Works

Isoliquiritigenin inhibits the NF-κB signaling cascade by blocking IκB kinase (IKK) phosphorylation, thereby suppressing downstream transcription of pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β. It activates AMP-activated protein kinase (AMPK), which enhances fatty acid oxidation and improves insulin receptor substrate-1 (IRS-1) signaling, contributing to its insulin-sensitizing effects. Additionally, isoliquiritigenin acts as a partial agonist at PPARγ receptors and inhibits aromatase (CYP19A1), influencing both lipid homeostasis and estrogen biosynthesis.

Scientific Research

Human clinical evidence for isoliquiritigenin is limited, with only one small RCT (n=60) testing a licorice flavonoid extract containing ~1.5% ILTG at 150 mg/day for metabolic syndrome (PMID: 23380324), and one pilot study (n=15) using 100 mg/day pure ILTG for anti-inflammatory effects (PMID: 28494188). No high-quality RCTs exist for cancer, neurodegeneration, or skin conditions, with most evidence derived from preclinical studies (PMID: 34684391).

Clinical Summary

A randomized controlled trial in postmenopausal women with metabolic syndrome (n=60) demonstrated a 15% reduction in serum triglycerides and a 12% improvement in HOMA-IR after supplementation, providing moderate-quality evidence for metabolic benefit (PMID: 23380324). A preliminary study in healthy volunteers reported a 20% reduction in C-reactive protein, though the small sample size and short duration limit conclusions. The majority of mechanistic evidence derives from in vitro cell culture studies and rodent models, where doses of 10–50 mg/kg/day consistently reduced inflammatory markers and improved lipid profiles. Robust phase II or III human clinical trials are currently lacking, meaning evidence strength for most claimed benefits remains preliminary to moderate.

Nutritional Profile

Isoliquiritigenin (ISL) is a chalcone-type flavonoid (C₁₅H₁₂O₄, MW 256.25 g/mol) primarily found in licorice root (Glycyrrhiza glabra/uralensis), at concentrations of approximately 0.05–0.3% of dry root weight. It is not a macronutrient or micronutrient source; its value is entirely as a bioactive polyphenolic compound. ISL is lipophilic with moderate water solubility (~0.1 mg/mL). Oral bioavailability in humans is estimated at 5–15% due to extensive Phase II metabolism (glucuronidation and sulfation in the intestine and liver, primarily via UGT1A1 and SULT1A1). Peak plasma concentrations following a 100 mg oral dose are estimated at 0.2–0.8 µM, with a Tmax of 1–3 hours. Enterohepatic recycling may produce a secondary plasma peak. ISL is a potent activator of the Nrf2/ARE/HO-1 antioxidant pathway, an inhibitor of NF-κB and NLRP3 inflammasome signaling, and a modulator of aldose reductase and PPARγ. It also functions as a phytoestrogen with selective estrogen receptor β (ERβ) affinity (IC₅₀ ~1–5 µM). Co-administration with a lipid-based carrier or piperine (5–10 mg) may improve bioavailability by 30–60%.

Preparation & Dosage

Clinically studied doses include 2.25 mg ILTG daily as part of standardized licorice extract (150 mg containing 1.5% ILTG) for 8 weeks, or 100 mg/day pure ILTG powder in divided doses for 4 weeks. Commercial supplements typically provide 5-20 mg pure ILTG in capsules. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

ISL pairs synergistically with (1) Piperine (5–10 mg) — inhibits hepatic and intestinal glucuronidation (UGT and CYP3A4 inhibition), increasing ISL oral bioavailability by an estimated 30–60%; (2) Curcumin (200–500 mg, as enhanced-bioavailability form) — both compounds converge on NF-κB and Nrf2 pathways, providing additive anti-inflammatory and antioxidant effects, with curcumin additionally suppressing COX-2 while ISL targets NLRP3 inflammasome; (3) Berberine (500 mg) — complements ISL's metabolic benefits by activating AMPK, enhancing insulin sensitization and triglyceride reduction through a parallel but distinct mechanism (AMPK vs. PPARγ modulation); (4) Quercetin (250–500 mg) — as a fellow flavonoid, quercetin synergizes with ISL in Nrf2/HO-1 activation and shares Phase II metabolic pathways, potentially extending the half-life of both compounds through competitive inhibition of sulfotransferases. Together, this stack targets metabolic syndrome markers (triglycerides, insulin resistance, systemic inflammation) through complementary molecular pathways.

Safety & Interactions

Isoliquiritigenin shares structural similarities with phytoestrogens and may interact with estrogen receptor signaling, making use in hormone-sensitive conditions such as estrogen receptor-positive breast cancer, uterine fibroids, or endometriosis potentially contraindicated. Because it inhibits CYP19A1 (aromatase) and may affect CYP3A4 activity, co-administration with estrogen therapies, tamoxifen, or drugs with narrow therapeutic windows metabolized by CYP3A4 warrants caution. High doses in animal models have shown mild hepatotoxic signals, though human data on liver safety at supplemental doses are insufficient. Pregnancy and breastfeeding safety has not been established, and use should be avoided in these populations pending further study.